3,5-dimethyl-1-phenylpiperazine | 6139-65-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3,5-dimethyl-1-phenylpiperazine
• 英文别名: 3,5-dimethyl-1-phenyl-piperazine；cis-4-Phenyl-2,6-dimethyl-piperazin；cis-4-Phenyl-2,6-dimethylpiperazin；(3R,5S)-3,5-dimethyl-1-phenylpiperazine
• CAS: 6139-65-7
• 化学式: C₁₂H₁₈N₂
• 分子量: 190.288
• InChiKey: RADPVVIPUAGLPO-PHIMTYICSA-N

物化性质

• 沸点：
  301.5±17.0 °C(Predicted)
• 密度：
  0.962±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  氯苯 、 2,6-dimethylpiperazine 在 2-甲基-2-丁醇 2,2'-联吡啶 、 nickel diacetate 、 sodium hydride 、 苯乙烯 作用下， 以 四氢呋喃 为溶剂， 反应 11.0h， 以69%的产率得到3,5-dimethyl-1-phenylpiperazine
  参考文献：
  名称：

  镍催化仲二胺的选择性N-芳基化或N，N'-二芳基化

  摘要：

  描述了使用与2,2'-联吡啶缔合的Ni（0）的催化剂组合，从相应的二胺和芳基氯化物选择性合成N-芳基或N，N'-二芳基哌嗪和三亚甲基（双）哌啶。Ni / 2，2'-联吡啶催化剂对于哌嗪的顺序芳基化也是有效的。报道了新型和不对称的1，4-二芳基哌嗪的制备。

  DOI：

  10.1016/s0040-4020(02)00750-0

文献信息

• Compounds
  申请人：AstraZeneca AB

  公开号：US10301267B2

  公开（公告）日：2019-05-28

  There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.

  本发明提供了一种式 (I) 的化合物： 或其药学上可接受的盐。此外，还提供了式 1 化合物的生产工艺，以及式 1 化合物作为药物和治疗癌症的用途。
• ACYLAMINOPYRAZOLES AS FGFR INHIBITORS
  申请人：AstraZeneca AB

  公开号：EP2125748B1

  公开（公告）日：2011-05-25
• NOVEL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：US20170260143A1

  公开（公告）日：2017-09-14

  There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
• SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：US20210186963A1

  公开（公告）日：2021-06-24

  A compound, or a pharmaceutically acceptable salt or ester thereof, according to formula I: R 20 —(Z) b —(Y) c —(R 21 ) a —(X) d —R 22 —R 23 wherein R 20 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; Z is alkanediyl, substituted alkanediyl, cycloalkanediyl, or substituted cycloalkanediyl; Y is S, O, S(═O), S(═O)(═O)—, or NR 10 , wherein R 10 is H or alkyl; R 21 is alkanediyl, substituted alkanediyl, cycloalkanediyl, substituted cycloalkanediyl, alkadienyl, substituted alkadienyl, cycloalkenediyl, substituted cycloalkenediyl, alkatrienyl, substituted alkatrienyl; X is —C(═O)—, —S(═O)(═O)—, or —N(H)C(═O)—; R 22 includes at least one divalent amino radical; R 23 is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a thio-containing group, or a seleno-containing group; a, b, c, and d independently are 0 or 1.
• US9688640B2
  申请人：——

  公开号：US9688640B2

  公开（公告）日：2017-06-27